Foundayo: What to Know About the New Oral GLP-1 Pill

Foundayo is a newer oral GLP-1 medication, generic name orforglipron, approved for both type 2 diabetes and weight management, a genuinely distinct option in the growing oral GLP-1 category.

How Foundayo Differs From Other Oral Options

Unlike Rybelsus and the newer Ozempic tablet, which are oral forms of semaglutide, Foundayo uses a different active ingredient entirely, orforglipron, a non-peptide GLP-1 receptor agonist.

What This Means for Patients

A non-peptide oral GLP-1 medication represents real, genuine pharmaceutical innovation, potentially offering more consistent absorption than peptide-based oral formulations, which typically require strict dosing conditions like an empty stomach.

Bottom Line

Foundayo adds a genuinely distinct option to the GLP-1 landscape, worth discussing directly with your provider if oral treatment is a priority for you.

Related Reading

Retatrutide: The Investigational "Triple Agonist" Drug Explained

Does GLP-1 Cause Hair Loss?

Can GLP-1 Medications Help With Alcohol Use Disorder?

FDA's Concerns With Unapproved and Compounded GLP-1 Drugs

For the full GLP-1 knowledge base, explore DietApp's GLP-1 Tracker hub